Petros Pharmaceuticals

Petros Pharmaceuticals(PTPI)

NEW YORK, NY
Pharmaceutical

Focus: Men's Health

Petros Pharmaceuticals is a life sciences company focused on Men's Health.

Neurology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Cold environment participants with spinal cord injury
Spinal Cord Injuries
N/A
Clinical Trials (1)
NCT04215939Assessment of Vasomotion of People With Spinal Cord Injury
N/A
Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue
Obese
N/A
Clinical Trials (1)
NCT04039685The Effects of Chronic Exercise on UCP1 Gene in Human White Adipose Tissue
N/A
Exercise with cooling
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT04125628Exercise on Multiple Sclerosis Patients
N/A
Cold exposure
Obesity
N/A
Clinical Trials (1)
NCT04037371Environmental Temperature and Human White Adipose Tissue
N/A
Work/ rest scenario
Risk of Heat Stress
N/A
Clinical Trials (1)
NCT04160728Occupational Heat Stress on Workers' Productivity
N/A
Shuttle run test
Risk of Heat Stress
N/A
Clinical Trials (1)
NCT04241900Effect of Aging and Aerobic Fitness Level on Heat Dissipation
N/A
Radiation and warm environment
Heat Stress
N/A
Clinical Trials (1)
NCT04160741Effects of Solar Radiation on Human Function and Cognition
N/A
Thermal stress and performance using a pre-cooling protocol
Risk of Heat Stress
N/A
Clinical Trials (1)
NCT04197375Impact of Pre-cooling in Adolescent Tennis Athletes
N/A
Colostrum supplementation for bone loss
Osteopenia
N/A
Clinical Trials (1)
NCT04040010The Effects of Bovine Colostrum in Bone Metabolism in Humans
N/A
Environmental Temperature and White Adipose Tissue in Cancer Patients
Cancer Patients
N/A
Clinical Trials (1)
NCT04037410Environmental Temperature and White Adipose Tissue in Cancer Patients
N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2021
Portfolio: 10 clinical trials
SEC Filings: 2 available

Financials (FY2024)

Revenue
$6M3%
R&D Spend
$2M(41%)38%
Net Income
-$8M
Cash
$13M